Syngene International Limited has informed the Exchange regarding a press release dated January 19, 2026, titled "Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035".
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Syngene International has extended its long-term research collaboration with global pharma major Bristol Myers Squibb until 2035. The announcement was made via a press release dated January 19, 2026, shared with the stock exchange. Syngene is a leading Indian contract research organization (CRO), and the renewal with a top global drugmaker signals continued trust in its research capabilities. Extending the tie-up until 2035 provides the company with several more years of revenue visibility under a long-term deal. The specific financial terms of the extension were not disclosed in the filing.
Positive for shareholders — a multi-year extension with a top global pharmaceutical company strengthens Syngene's revenue visibility, reduces business uncertainty, and is likely to be viewed favorably by the market.